Novo Nordisk's Ryzodeg misses superiority endpoint in Phase III
This article was originally published in Scrip
Novo Nordisk's Ryzodeg, sister compound to Tresiba (insulin degludec), has failed to meet its primary endpoint in a Phase IIIb trial.
You may also be interested in...
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.